Company intelligence / Profile preview
POLYSAN
- Ownership
- Private
- Development stage
- Other
Overview
POLYSAN is a leading Russian pharmaceutical company with several original drugs on the market, including Cycloferon (an immunomodulator/antiviral), Reamberin (a succinic acid-based infusion for detoxification), and Cytoflavin (a metabolic agent). The company has a strong R&D focus with 8 new products reportedly in development. Its products are registered in Russia and exported to 17 countries. Clinical results for marketed drugs have led to their inclusion in federal treatment standards for various infectious diseases[1][2][5].
- Therapeutic areas
- OtherInfectious Diseases
- Modalities
- Small moleculeBiologic (for some products)
- Industry
- Biotech
Drug pipeline
7 assets6 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on POLYSAN.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on POLYSAN.